Order Xeomin® Online for Clinics

Xeomin® (incobotulinumtoxinA) is a botulinum toxin type A supplied as a lyophilized powder that is reconstituted with preservative-free saline before intramuscular or intraglandular injection. Licensed clinics, hospitals and healthcare professionals can order it for aesthetic and therapeutic injection programs, from glabellar line treatment to the neurologic and sialorrhea indications in the US labeling. Injection is performed only by clinicians trained in botulinum toxin technique and in the anatomy of the target muscles or glands.

How incobotulinumtoxinA works and where it fits in practice

IncobotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNAP-25, a protein nerve endings need to release their signal. The treated muscle or gland receives less stimulation, which reduces contraction or secretion. The effect is temporary, because nerve terminals gradually recover function.

Clinical onset is usually seen within the first days after injection, and duration varies by indication, dose and injection pattern. For moderate to severe glabellar lines, the US prescribing information states that treatment should not be repeated more often than every three months. Therapeutic indications follow their own labeled intervals and dose ranges, so each protocol should be written separately rather than carried over from aesthetic practice.

In an aesthetic treatment room, Xeomin sits alongside neuromodulators used for upper-face dynamic lines. In neurology, rehabilitation and ENT settings, the same molecule is used for cervical dystonia, blepharospasm, upper limb spasticity and chronic drooling. Units are specific to this preparation and cannot be converted from another botulinum toxin product.

Labeled uses and off-label considerations

The US labeling for Xeomin covers chronic sialorrhea, upper limb spasticity, cervical dystonia, blepharospasm in patients previously treated with onabotulinumtoxinA, and moderate to severe glabellar lines in adults. Several of these indications include pediatric populations; the labeling defines the ages and dose limits that apply. Review the current prescribing information before building or revising a clinic protocol.

Injection of other facial areas, such as lateral canthal or forehead lines, is not part of the US labeling for this product. Any such use is off-label, is a clinical decision for the treating physician, and should be documented as off-label in the patient record. It is not promoted or recommended here.

Why it matters: Dose units, dilution and injection sites differ by indication, so one standing protocol cannot safely cover both aesthetic and therapeutic treatment.

Xeomin wholesale ordering and vial quantities for clinics

Clinics can view current Xeomin wholesale pricing and select the vial quantity shown during ordering, then match that quantity to scheduled treatment days. Because reconstituted vials have a short in-use window, many practices order to a predictable injection calendar rather than holding long surplus. Group treatment sessions where possible so a reconstituted vial is used efficiently.

Ordering is intended for licensed clinics and healthcare professionals, and professional-use ordering or clinic documentation requirements may apply. We may review order details before processing. Med Wholesale Supplies is a wholesale supplier of aesthetic, orthopedic and medical products to clinics, hospitals and medical professionals, operating since 2013.

When planning inventory, account for the number of injectors on staff, typical units used per indication, and the lead time your practice needs between restock cycles. Keep a simple log of vials on hand with lot numbers and expiry dates so stock rotation is predictable.

Reconstitution, receiving and storage practice

Reconstitution is performed with preservative-free 0.9% sodium chloride injection using aseptic technique. The prescribing information instructs that the vial be reconstituted gently rather than shaken vigorously, and that vials showing no vacuum draw of diluent not be used. Vials are single-use and contain no preservative, so each reconstituted vial should serve one session.

Per US labeling, unopened vials may be stored at room temperature, refrigerated, or frozen within the ranges stated on the label, while reconstituted product is kept refrigerated and used within 24 hours. Label each reconstituted vial with the date and time of reconstitution. Confirm the storage figure on the carton against your own treatment-room records.

• Check lot number and expiry date against the packing documentation at receipt.
• Inspect cartons and vials for damage or missing seals before stocking.
• Record reconstitution diluent volume and resulting concentration for each session.
• Keep vials in their original carton until the day of use.
• Dispose of used vials, syringes and unused reconstituted product according to local requirements and your clinical waste policy.

Patient selection, contraindications and precautions

The US prescribing information carries a boxed warning for distant spread of toxin effect. Symptoms such as generalized muscle weakness, swallowing difficulty, speech changes or breathing problems can appear hours to weeks after injection, and have been reported with doses comparable to those used for cervical dystonia as well as lower doses. Counsel patients and caregivers to seek urgent care if these symptoms occur.

Xeomin is contraindicated in patients with known hypersensitivity to botulinum toxin preparations or any component of the formulation, and in patients with infection at the planned injection site. Document these checks as part of your pre-treatment assessment.

• Pre-existing neuromuscular disease, such as myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis or motor neuropathy, raises the risk of clinically significant systemic effects.
• Pre-existing swallowing or breathing difficulty increases risk, particularly in cervical dystonia treatment.
• Recent treatment with any botulinum toxin product shortens the safe interval before retreatment.
• Blepharospasm patients may have reduced blinking and risk of corneal exposure; protective eye measures may be needed.
• The formulation contains human serum albumin, a blood-derived component; the label notes a theoretical risk of viral transmission.
• Data in pregnancy and lactation are limited, so treatment is an individualized clinical decision.

Side effects, interactions and monitoring

Reported adverse reactions depend on the indication and injection site. In glabellar line treatment, headache is among the most commonly reported effects. In cervical dystonia, dysphagia, neck pain and muscle weakness are reported; in blepharospasm, eyelid ptosis, dry eye and dry mouth; in chronic sialorrhea, dry mouth and swallowing difficulty; in upper limb spasticity, injection site pain and falls. Local injection site reactions, bruising and transient weakness of nearby muscles can occur in any setting.

Caution is advised with aminoglycoside antibiotics and other agents that interfere with neuromuscular transmission, including curare-like compounds and muscle relaxants, because they may potentiate toxin effects. Anticholinergic medicines may add to systemic anticholinergic effects when treating sialorrhea. Take a full medication history, including recent botulinum toxin from any source, before injecting.

Monitoring is mostly clinical. Review swallowing, breathing, eyelid function and muscle strength at follow-up, assess response before scheduling retreatment, and keep treatment intervals within labeled limits. Advise patients to contact the clinic promptly if weakness, vision change, voice change or swallowing difficulty develops after injection, and to seek emergency care for breathing problems.

How it compares with other botulinum toxin type A products

All botulinum toxin type A products act on the same pathway, but they are not interchangeable in units, dilution or labeled indications. Doses cannot be converted between brands, and each product has its own storage, reconstitution and retreatment guidance. Clinics that stock more than one neuromodulator should keep separate written protocols and separate storage positions to reduce selection error.

The manufacturer describes incobotulinumtoxinA as a formulation free from complexing proteins. That is a formulation characteristic, not a claim of superior results or duration. Product choice in practice usually comes down to the indications a clinic treats, the storage conditions the labeling allows, injector familiarity and ordering logistics.

Treatment-room workflow and documentation

Before each session, confirm patient identity, indication, consent and any change in medical or medication history. Record the lot number, expiry date, diluent volume, total units injected and each injection site in the chart. These entries support continuity between injectors and are important if an adverse event is later reported.

Staff readiness matters as much as stock. Injectors should be trained in the relevant anatomy and dosing for each indication they treat, and clinical staff should know how to triage a post-injection call about swallowing, breathing or vision. Keep the current prescribing information accessible in the treatment area, and review it whenever the labeling is updated.

Quick tip: Keep a written reconstitution card at the preparation station so diluent volume and concentration stay consistent across staff.

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.